Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells
US9849128B2 · kind B2 · utility
23Cited by
20References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 10, 2017 |
| Grant date | Dec 26, 2017 |
| Priority date | — |
| Expiry date | Mar 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q1/485
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.